JP2025516719A - Nlrp3を阻害するためのオキソインドリニルアミド誘導体およびその使用 - Google Patents
Nlrp3を阻害するためのオキソインドリニルアミド誘導体およびその使用 Download PDFInfo
- Publication number
- JP2025516719A JP2025516719A JP2024567587A JP2024567587A JP2025516719A JP 2025516719 A JP2025516719 A JP 2025516719A JP 2024567587 A JP2024567587 A JP 2024567587A JP 2024567587 A JP2024567587 A JP 2024567587A JP 2025516719 A JP2025516719 A JP 2025516719A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- compound
- halo
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263341614P | 2022-05-13 | 2022-05-13 | |
| US63/341,614 | 2022-05-13 | ||
| PCT/US2023/066934 WO2023220715A1 (en) | 2022-05-13 | 2023-05-12 | Oxoindolinyl amide derivatives for inhibiting nlrp3 and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025516719A true JP2025516719A (ja) | 2025-05-30 |
| JP2025516719A5 JP2025516719A5 (enExample) | 2026-05-21 |
Family
ID=86760226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024567587A Pending JP2025516719A (ja) | 2022-05-13 | 2023-05-12 | Nlrp3を阻害するためのオキソインドリニルアミド誘導体およびその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240368131A1 (enExample) |
| EP (1) | EP4522591A1 (enExample) |
| JP (1) | JP2025516719A (enExample) |
| KR (1) | KR20240172228A (enExample) |
| CN (1) | CN119212978A (enExample) |
| AU (1) | AU2023268557A1 (enExample) |
| CA (1) | CA3251062A1 (enExample) |
| CL (1) | CL2024003460A1 (enExample) |
| CO (1) | CO2024015371A2 (enExample) |
| IL (1) | IL316674A (enExample) |
| JO (2) | JOP20240257A1 (enExample) |
| MX (1) | MX2024013978A (enExample) |
| PE (1) | PE20251252A1 (enExample) |
| TW (1) | TW202409013A (enExample) |
| WO (1) | WO2023220715A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026510921A (ja) * | 2023-03-17 | 2026-04-10 | ヴェンタス・セラピューティクス・ユー・エス・インコーポレイテッド | Nlrp3を阻害するためのアミド誘導体及びその使用 |
| WO2025106863A1 (en) * | 2023-11-15 | 2025-05-22 | Ventus Therapeutics U.S., Inc. | Lactam derivatives for inhibiting nlrp3 and uses thereof |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| UY38687A (es) * | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
-
2023
- 2023-05-12 WO PCT/US2023/066934 patent/WO2023220715A1/en not_active Ceased
- 2023-05-12 AU AU2023268557A patent/AU2023268557A1/en active Pending
- 2023-05-12 PE PE2024002511A patent/PE20251252A1/es unknown
- 2023-05-12 EP EP23730335.9A patent/EP4522591A1/en active Pending
- 2023-05-12 CN CN202380040044.4A patent/CN119212978A/zh active Pending
- 2023-05-12 IL IL316674A patent/IL316674A/en unknown
- 2023-05-12 JP JP2024567587A patent/JP2025516719A/ja active Pending
- 2023-05-12 CA CA3251062A patent/CA3251062A1/en active Pending
- 2023-05-12 KR KR1020247038886A patent/KR20240172228A/ko active Pending
- 2023-05-12 TW TW112117756A patent/TW202409013A/zh unknown
-
2024
- 2024-06-26 US US18/754,527 patent/US20240368131A1/en active Pending
- 2024-11-12 MX MX2024013978A patent/MX2024013978A/es unknown
- 2024-11-12 JO JOJO/P/2024/0257A patent/JOP20240257A1/ar unknown
- 2024-11-12 CL CL2024003460A patent/CL2024003460A1/es unknown
- 2024-11-12 CO CONC2024/0015371A patent/CO2024015371A2/es unknown
- 2024-11-12 JO JOJO/P/2024/0258A patent/JOP20240258A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20240257A1 (ar) | 2024-11-12 |
| CL2024003460A1 (es) | 2025-04-11 |
| MX2024013978A (es) | 2024-12-06 |
| JOP20240258A1 (ar) | 2024-11-12 |
| KR20240172228A (ko) | 2024-12-09 |
| CA3251062A1 (en) | 2023-11-16 |
| CO2024015371A2 (es) | 2024-12-30 |
| IL316674A (en) | 2024-12-01 |
| US20240368131A1 (en) | 2024-11-07 |
| PE20251252A1 (es) | 2025-05-06 |
| EP4522591A1 (en) | 2025-03-19 |
| CN119212978A (zh) | 2024-12-27 |
| WO2023220715A1 (en) | 2023-11-16 |
| AU2023268557A1 (en) | 2024-11-14 |
| TW202409013A (zh) | 2024-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12503475B2 (en) | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists | |
| JP2024050527A (ja) | Nlrp3を阻害するためのピリダジン化合物 | |
| CN110769821A (zh) | 作为il-17调节剂的螺环吲哚啉类 | |
| AU2018391675A1 (en) | Sulphonyl urea derivatives as NLRP3 inflammasome modulators | |
| KR20240172228A (ko) | Nlrp3을 억제하기 위한 옥소인돌리닐 아미드 유도체 및 이의 용도 | |
| KR20250005125A (ko) | NLRP3 유도체로서 유용한 피리도-[3,4-d]피리다진 아민 유도체 | |
| EP3983407B1 (en) | Sulfonylurea derivatives and uses thereof | |
| EP3983387B1 (en) | Sulfonylurea derivatives and uses thereof | |
| JP2025507852A (ja) | 中環状または大環状ベンジル置換複素環誘導体および関連の使用 | |
| US12312351B2 (en) | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors | |
| EP4486445A1 (en) | Bicyclic-heterocycle derivatives and related uses | |
| CN113474333A (zh) | 新的经取代的磺酰脲类衍生物 | |
| WO2020249669A1 (en) | Sulfonamide derivatives and uses thereof | |
| CA3259558A1 (en) | COMPOUNDS FOR THE TREATMENT OF CORONAVIRUS INFECTION | |
| EA051595B1 (ru) | Соединения пиридазина для ингибирования nlrp3 | |
| KR20230157535A (ko) | Nlrp3을 저해하기 위한 피리다진 화합물 | |
| HK40039990B (en) | Sulphonyl urea derivatives as nlrp3 inflammasome modulators | |
| HK40039990A (en) | Sulphonyl urea derivatives as nlrp3 inflammasome modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260512 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260512 |